An international expert group convened by the American Diabetes Association proposed that the criterion for diabetes remission be an HbA1c level below 6.5%, measured at least three months after glucose-lowering drugs are stopped.
Continuous glucose monitoring (CGM) was associated with improved HbA1c levels among adolescents and young adults in one trial and less hypoglycemia among older adults in another.
A study used simulation modeling to project the long-term effects of a three-month exercise and cognitive behavioral therapy (CBT) intervention for patients with type 2 diabetes and major depressive disorder. It found clear cost-effectiveness with
In a survey of U.S. adults with diabetes, about 13% who were prescribed medication said they did not take it as prescribed, and about 24% said they asked their doctors for a lower-cost medication.
The score, which was based on cardiac troponin, N-terminal pro-B-type natriuretic peptide, C-reactive protein, and electrocardiography, could be used to target specific therapies to the highest-risk patients, study authors said.
The industry-funded PIONEER 3 trial randomized adults whose type 2 diabetes was uncontrolled with metformin, with or without sulfonylurea, to receive either oral sitagliptin (100 mg/d) or oral semaglutide (3, 7, or 14 mg/d).
British patients with type 1 diabetes were enrolled in group training courses that taught flexible intensive insulin treatment and then randomized to an insulin pump or multiple daily injections and followed for two years.
Prior metformin use was associated with a threefold decrease in mortality from COVID-19 in one study of patients with type 2 diabetes, while three other studies found mixed results on whether dipeptidyl peptidase-4 (DPP-4) inhibitors affect COVID-19
A randomized trial found equivalent improvements in visual acuity at two years with either therapy but identified some differences in outcomes that could help patients and clinicians choose a treatment method.
The trial of semaglutide included 3,297 patients with type 2 diabetes, 83% of whom had established cardiovascular disease, chronic kidney disease, or both.